Profile data is unavailable for this security.
About the company
Aurinia Pharmaceuticals Inc. is a biopharmaceutical company. The Company is focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. It has developed LUPKYNIS (voclosporin), an oral therapy for the treatment of adult patients with active lupus nephritis (LN) and continues to conduct clinical and regulatory activities to support the LUPKYNIS development program. The Company is also developing aritinercept (AUR200), a dual inhibitor of B cell-activating factor (BAFF) and a proliferation-inducing ligand (APRIL) for the potential treatment of autoimmune diseases. It sells LUPKYNIS to specialty pharmacies and a specialty distributor in the United States and sells LUPKYNIS inventory to its collaboration partner, Otsuka Pharmaceutical Co., Ltd. (Otsuka), for the European and Japanese market. The Company sells encapsulated voclosporin to its collaboration partner, Otsuka, which Otsuka then sells to customers in its territories.
- Revenue in USD (TTM)283.06m
- Net income in USD287.20m
- Incorporated2009
- Employees300.00
- LocationAurinia Pharmaceuticals Inc#140, 14315 - 118 AVENUEEDMONTON T5L 4S6CanadaCAN
- Phone+1 (250) 744-2487
- Fax+1 (250) 708-4345
- Websitehttps://www.auriniapharma.com
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| EyePoint Inc | 42.34m | -205.75m | 1.52bn | 165.00 | -- | 6.37 | -- | 35.82 | -2.99 | -2.99 | 0.617 | 2.88 | 0.1532 | 1.02 | 59.51 | 256,606.10 | -74.47 | -35.88 | -86.87 | -42.05 | 94.08 | 84.82 | -485.95 | -201.78 | 7.11 | -- | 0.00 | -- | -5.97 | 16.27 | -84.86 | -- | 80.24 | -- |
| Perrigo Company PLC | 4.25bn | -1.40bn | 1.57bn | 8.10k | -- | 0.5339 | -- | 0.3686 | -10.19 | -10.36 | 30.80 | 21.33 | 0.4678 | 2.47 | 6.37 | 525,074.10 | -15.42 | -3.52 | -17.39 | -4.03 | 35.14 | 34.70 | -32.97 | -8.36 | 1.63 | 1.91 | 0.5536 | -- | -2.75 | 0.794 | -772.62 | -- | -14.60 | 5.21 |
| Harmony Biosciences Holdings Inc | 868.45m | 158.69m | 1.64bn | 293.00 | 10.42 | 1.88 | 8.89 | 1.88 | 2.71 | 2.71 | 14.87 | 15.07 | 0.7649 | 31.60 | 9.66 | 2,964,004.00 | 13.98 | 17.23 | 17.21 | 20.92 | 77.16 | 78.84 | 18.27 | 22.32 | 3.58 | -- | 0.1583 | -- | 21.51 | 40.30 | 9.07 | -- | 528.16 | -- |
| Immunocore Holdings PLC - ADR | 400.02m | -35.51m | 1.64bn | 524.00 | -- | 4.30 | -- | 4.10 | -0.7057 | -0.7057 | 7.87 | 7.52 | 0.3852 | 0.8348 | 5.84 | 763,389.30 | -3.42 | -11.69 | -4.39 | -14.93 | 98.73 | -- | -8.88 | -32.06 | 4.01 | -- | 0.5078 | -- | 28.95 | 59.62 | 30.48 | -- | 1.95 | -- |
| Innoviva Inc | 411.33m | 271.17m | 1.65bn | 159.00 | 7.20 | 1.42 | 5.30 | 4.02 | 3.10 | 3.10 | 5.18 | 15.71 | 0.2802 | 2.84 | 4.58 | 2,586,969.00 | 18.47 | 17.66 | 20.46 | 19.58 | 74.80 | -- | 65.92 | 58.96 | 13.85 | -- | 0.1802 | -- | 14.67 | 4.08 | 1,059.22 | 3.86 | 281.45 | -- |
| Sarepta Therapeutics Inc | 2.20bn | -713.41m | 1.67bn | 835.00 | -- | 1.46 | -- | 0.7578 | -7.20 | -7.20 | 21.50 | 10.87 | 0.6012 | 0.8101 | 4.40 | 2,632,619.00 | -19.51 | -12.81 | -26.01 | -15.87 | 69.33 | 80.21 | -32.45 | -30.61 | 1.48 | -21.14 | 0.4209 | -- | 15.58 | 32.41 | -403.27 | -- | 5.09 | -- |
| Veradermics Inc | 0.00 | -53.81m | 1.68bn | 19.00 | -- | -- | -- | -- | -1.53 | -1.53 | 0.00 | 0.3731 | -- | -- | -- | 0.00 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -60.63 | -- | -- | -- |
| ANI Pharmaceuticals Inc | 883.37m | 70.21m | 1.71bn | 970.00 | 22.85 | 3.17 | 10.12 | 1.93 | 3.33 | 3.33 | 42.25 | 24.03 | 0.6484 | 2.44 | 3.51 | 910,686.60 | 5.75 | -0.2549 | 6.96 | -0.3002 | 61.36 | 59.78 | 8.87 | -0.473 | 2.19 | 6.52 | 0.533 | -- | 43.78 | 33.48 | 448.52 | -- | 17.66 | -- |
| Vericel Corp | 276.26m | 16.52m | 1.75bn | 398.00 | 130.61 | 4.91 | 61.89 | 6.32 | 0.2633 | 0.2633 | 5.26 | 7.01 | 0.6001 | 4.05 | 3.78 | 694,118.10 | 3.59 | -0.0292 | 4.02 | -0.0331 | 74.42 | 70.68 | 5.98 | -0.0467 | 4.68 | -- | 0.0056 | -- | 16.45 | 17.34 | 59.41 | 41.97 | 59.56 | -- |
| Organon & Co | 6.22bn | 187.00m | 1.80bn | 10.00k | 9.63 | 2.39 | 3.28 | 0.289 | 0.7166 | 0.7166 | 23.86 | 2.89 | 0.4787 | 2.13 | 4.62 | 621,600.00 | 1.44 | 7.45 | 1.79 | 9.65 | 53.30 | 59.42 | 3.01 | 13.85 | 1.23 | 2.62 | 0.92 | 25.68 | -2.92 | -0.9868 | -78.36 | -39.23 | 4.38 | -- |
| Aurinia Pharmaceuticals Inc | 283.06m | 287.20m | 1.88bn | 300.00 | 6.80 | 3.22 | 6.14 | 6.65 | 2.08 | 2.08 | 2.04 | 4.39 | 0.4347 | 0.7693 | 7.26 | -- | 44.11 | -2.73 | 51.71 | -3.10 | 88.46 | 90.63 | 101.47 | -8.50 | 4.76 | -- | 0.1059 | -- | 20.38 | 41.38 | 4,893.08 | -- | -49.05 | -- |
| Phibro Animal Health Corp | 1.46bn | 92.09m | 2.12bn | 2.48k | 23.17 | 6.37 | 14.83 | 1.45 | 2.26 | 2.26 | 35.88 | 8.21 | 1.09 | 2.09 | 7.18 | 591,646.40 | 6.84 | 3.89 | 8.47 | 4.87 | 32.56 | 31.14 | 6.29 | 3.69 | 1.22 | 4.39 | 0.6875 | 52.02 | 27.37 | 10.12 | 1,897.68 | 7.54 | 2.38 | 0.00 |
| Ultragenyx Pharmaceutical Inc | 673.00m | -575.00m | 2.13bn | 1.37k | -- | -- | -- | 3.17 | -5.83 | -5.83 | 6.83 | -0.8282 | 0.4434 | 2.25 | 4.81 | 490,882.60 | -37.89 | -37.78 | -50.15 | -45.91 | 83.80 | 88.44 | -85.44 | -122.25 | 2.34 | -14.66 | 1.07 | -- | 20.13 | 19.95 | -1.02 | -- | -13.71 | -- |
Data as of Mar 03 2026. Currency figures normalised to Aurinia Pharmaceuticals Inc's reporting currency: US Dollar USD
29.16%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Tang Capital Management LLCas of 05 Aug 2025 | 11.33m | 8.59% |
| BlackRock Fund Advisorsas of 31 Dec 2025 | 6.59m | 5.00% |
| Armistice Capital LLCas of 31 Dec 2024 | 6.40m | 4.85% |
| Arrowstreet Capital LPas of 31 Dec 2025 | 3.39m | 2.57% |
| SSgA Funds Management, Inc.as of 31 Dec 2025 | 2.50m | 1.90% |
| Two Sigma Investments LPas of 31 Dec 2025 | 1.96m | 1.49% |
| Renaissance Technologies LLCas of 31 Dec 2025 | 1.59m | 1.21% |
| Marshall Wace LLPas of 31 Dec 2025 | 1.57m | 1.20% |
| Morgan Stanley & Co. LLCas of 31 Dec 2025 | 1.57m | 1.19% |
| D. E. Shaw & Co. LPas of 31 Dec 2025 | 1.53m | 1.16% |
More ▼
Data from 31 Dec 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
